Statin Trial Shows 30% Cut in First Heart Events for Australians Over 70

A decade-long randomised control trial involving almost 10,000 Australians aged 70 and older found that daily statin therapy reduced the risk of a first major cardiovascular event—heart attack, stroke, or heart surgery—by 30 percent. In practical terms, one such event could be prevented for every 37 participants treated for roughly six years. The study also reported no statistically significant difference in dementia rates between the statin and placebo groups and no improvement in disability-free survival.

The Guardian

Researchers recruited participants through nearly 3,400 general practices across Australia, excluding anyone with prior heart attacks, existing statin prescriptions, unsafe health conditions, or lack of independent living. The cohort was predominantly white, with a mean age of about 75 years. Over the trial period, more than 15 percent of participants stopped taking the medication, indicating adherence challenges.

The Guardian

Adjunct Professor Mark Nelson of Monash University’s School of Public Health described the results as filling a critical evidence gap for an ageing population. Lead author Adjunct Professor Sophia Zoungas expressed hope that the strong evidence would prompt updates to treatment guidelines, encouraging clinicians to discuss statins with older patients. Cardiologist Professor James Chong of Westmead Hospital noted that, if the findings lead to broader statin use, the absolute reduction in heart-related events could be substantial, while cautioning that the largely white sample may limit global generalisability. Hobart-based cardiologist Professor Tom Marwick highlighted that the trial “closes the book” on concerns about statins increasing dementia risk, but also pointed out the disappointment that disability-free survival did not improve despite fewer heart events.

The Guardian

The trial’s demographic homogeneity and the 15 percent discontinuation rate raise questions about applicability to more diverse populations and real-world adherence. Additionally, the lack of impact on overall survival or quality-adjusted life years suggests that statins address specific cardiac events but do not alter broader ageing-related health burdens.

The Guardian

If guideline committees incorporate the evidence, clinicians may more readily prescribe statins to healthy seniors, potentially preventing one major cardiac event per 37 treated individuals. Ongoing monitoring of adherence and further studies in more ethnically diverse cohorts will be needed to confirm the benefits and address the noted limitations.

The Guardian